Article info

Original research
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.

Authors

  • Jara Palomero Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Carla Panisello Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Maria Lozano-Rabella Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ricky Tirtakasuma Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Judit Díaz-Gómez Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Daniela Grases Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Helena Pasamar Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Laura Arregui HUB-ICO-IDIBELL Biobank, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain PubMed articlesGoogle scholar articles
  • Eduard Dorca Duch Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain PubMed articlesGoogle scholar articles
  • Esther Guerra Fernández Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain PubMed articlesGoogle scholar articles
  • Ana Vivancos Cancer Genomics, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Carlos E de Andrea Pathology, Clinica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Ignacio Melero Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, SpainProgram of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research IDISNA, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Jordi Ponce Department of Gynaecology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain PubMed articlesGoogle scholar articles
  • August Vidal Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, SpainCentro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Josep Maria Piulats Medical Oncology, Catalan Institute of Oncology (ICO), IDIBELL-OncoBell, L'Hospitalet de Llobregat, Spain PubMed articlesGoogle scholar articles
  • Xavier Matias-Guiu Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, SpainCentro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, SpainPathology, Arnau de Vilanova University Hospital, University of LLeida, IRBLLEIDA, Lleida, Spain PubMed articlesGoogle scholar articles
  • Alena Gros Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Alena Gros; agros{at}vhio.net
View Full Text

Citation

Palomero J, Panisello C, Lozano-Rabella M, et al
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.

Publication history

  • Accepted November 25, 2022
  • First published December 29, 2022.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.